Entero Therapeutics ( ) - 株価, ニュースと分析Nasdaq:ENTO

ENTO 株式概要

エンターロ・セラピューティクス社は臨床段階にあるバイオ医薬品企業で、消化器疾患患者を対象とした標的治療薬および経口投与治療薬の開発に取り組んでいる。詳細

ENTO ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

過去5年間の収益は年間16.2%増加しました。

リスク分析

収益が 100 万ドル未満 ( $0 )

過去1年間で株主の希薄化は大幅に進んだ

キャッシュランウェイが1年未満である

意味のある時価総額がありません ( $2M )

+2 さらなるリスク

Entero Therapeutics, Inc. 競合他社

Sonnet BioTherapeutics Holdings

NasdaqCM:SONN

US$2.3m

GRI Bio

NasdaqCM:GRI

US$2.1m

Scorpius Holdings

NYSEAM:SCPX

US$2.8m

Salarius Pharmaceuticals

NasdaqCM:SLRX

US$2.2m

価格と性能

の歴代最高値、変動、値下がりまとめEntero Therapeutics
過去の株価
現在の株価	US$0.45
52週高値	US$14.51
52週安値	US$0.18
ベータ	1.22
11ヶ月の変化	-21.49%
3ヶ月変化	8.98%
1年変化	-90.53%
33年間の変化	-99.99%
5年間の変化	-100.00%
IPOからの変化	-100.00%

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

株主還元

	ENTO	US Biotechs	US 市場
7D	13.3%	4.3%	1.6%
1Y	-90.5%	18.8%	32.3%

業界別リターン: ENTO過去 1 年間で18.8 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: ENTOは、過去 1 年間で32.3 % のリターンを上げたUS市場を下回りました。

価格変動

Is ENTO's price volatile compared to industry and market?
ENTO volatility
ENTO Average Weekly Movement	27.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

安定した株価: ENTOの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ENTOの weekly volatility ( 28% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2014	9	James Sapirstein	www.enterothera.com

エンターロ・セラピューティクス社は、臨床段階にあるバイオ医薬品企業で、消化器疾患患者を対象とした標的治療薬および経口投与治療薬の開発に取り組んでいる。同社のパイプライン候補には、現在第2相試験中のグルテンを非免疫原性ペプチドに分解するセリアック病の標的経口バイオ治療薬ラティグルテナーゼや、胃不全麻痺の治療薬として第1相試験中の選択的5-HT4受容体部分作動薬カペセロドなどがある。また、脂肪やその他の栄養素の消化を可能にする組換えリパーゼ酵素であるアドルリパーゼの開発にも携わっており、嚢胞性線維症や慢性膵炎患者の外分泌膵不全の治療薬として現在フェーズ2試験中である；ニクロサミド：抗炎症作用を有する経口低分子化合物で、潰瘍性直腸炎および潰瘍性直腸シグモイド炎、免疫チェックポイント阻害剤関連大腸炎、転移性癌患者における下痢の治療薬として現在フェーズ2試験中。同社は以前First Wave BioPharma, Inc.として知られていたが、2024年5月にEntero Therapeutics, Inc.に社名を変更した。Entero Therapeutics, Inc.は2014年に法人化され、フロリダ州ボカラトンに本社を置いている。

Entero Therapeutics, Inc. 基礎のまとめ

Entero Therapeutics の収益と売上を時価総額と比較するとどうか。
ENTO 基礎統計学
時価総額	US$2.21m
収益（TTM）	-US$8.15m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-0.3x

PER（株価収益率

ENTO は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ENTO 損益計算書（TTM）
収益	US$0
売上原価	US$0
売上総利益	US$0
その他の費用	US$8.15m
収益	-US$8.15m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）	-1.71
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	0%

ENTO の長期的なパフォーマンスは？

過去の実績と比較を見る

ENTO 株式概要

報酬

リスク分析

Entero Therapeutics, Inc. 競合他社

NasdaqCM:SONN

US$2.3m

NasdaqCM:GRI

US$2.1m

NYSEAM:SCPX

US$2.8m

NasdaqCM:SLRX

US$2.2m

価格と性能

最新ニュース

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

Recent updates

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis